References
Stryer D, Bero LA. Characteristics of materials distributed by drug companies: an evaluation of appropriateness. J Gen Intern Med. 1996;11:575–83.
Yasuda SU, Woosley RL. The clinical value of FDA class C drugs approved from 1981–1988. Clin Pharmacol Ther. 1992;52:577–82.
Suresh CG, Greene D, Coupe MO. Use of adenosine and effectiveness of pharmaceutical marketing. Lancet. 1993;341:1540.
Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother. 1993;27:755–66.
Peltzman S. The diffusion of pharmaceutical innovation. In: Peltzman S, Helms RB, eds. Drug Development and Marketing. Washington, DC: AEI Center for Health Policy Research; 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beary, J.F. Pharmaceutical marketing has real and proven value. J Gen Intern Med 11, 635–636 (1996). https://doi.org/10.1007/BF02599032
Issue Date:
DOI: https://doi.org/10.1007/BF02599032